Moderna takes on IO Biotech
The group is expanding its mRNA-4359 trial to include first-line melanoma.
In triple-negative pumitamig concedes PD-L1-high disease
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
World Lung 2025 – pumitamig confirms its small-cell promise
Global data are in the same ballpark as Chinese results presented earlier this year.
Licensing analysis: big deals bolster biotech
PD-(L)1 x VEGF bispecifics prove a big draw.
ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
